Beard... It's abundantly clear that I'm wasting my time with you but you should know there's frequently a disconnect between the fundamentals of a company and the behavior of its stock. You should also know that one or two weeks of data are virtually useless. Why am I wasting my time????? Good luck with your investments. And congrats on your fabulous credentials, you're a truly impressive individual.
If you intend to post so frequently and loudly, you really should learn the English language. Your reading comprehension is horrendous and your writing is just as terrible. If your analytical skills were at least decent, I would've stayed away from this fray but there really is very little to justify your incredibly annoying verbosity. If nothing else, please learn the distinction between sales and stock price, which is what brad was referring to. You could also benefit from getting some perspective....on so much.
I've read your other posts and you sound like a fake and a phony. You certainly don't come across as a "scientifically skilled" person. In fact, you seem barely literate, unless English is a second or third language.
i should know better than to waste time on these boards. you should also tell all those biotechs to stop wasting time and money with clinical trials. and you probably should stop wasting time and money investing in biotechs.
Based on the royalty rate that the company will be receiving for its component in the triple-drug combination regimen, every billion dollars in sales that Abbvie generates will translate into $2 to $2.50 per share in net profits to Enanta, assuming a tax rate of about 20%. The express scripts deal means abbvie's drug will achieve rapid and substantial penetration. $4 billion is definitely doable in 2015, which means royalties to Enanta could total $8 to $10. Add in the $150 million in milestone payments, and the company will be receiving gobs of cash in the year ahead.
One also has to keep in mind that the profit margins that Abbvie earns is irrelevant to enanta since the royalties are based on sales, not profits.
Bottom lIne: ENTA is extraordinarily cheap at $50. The company could actually have some $500 million in cash by the end of 2015.
So are about 70% of all stocks. Keep on tossing stuff out, you're bound to be right about something at some point. NOW it's EOD. Always so tough to know when to take somebody seriously on these message boards. You're clearly not one of those people.
There's one piece of news out today, the stock is down pretty big, you can't say there's no connection between the two events, and you're throwing out a bunch of stuff with absolutely no basis. And I'm obviously wasting my time.
Please don't be so definitive when you obviously don't know, a fact that's made obvious by your ridiculous comment about CRL or black box.
I think you should say thank you for that entry point. After all, how much value was anyone giving the antibiotic program. Typical overreaction to something most don't understand.
if the ceo isn't doing his job then that means the r&d pipeline doesn't have good prospects. so, if the pipeline stinks and the ceo smells even worse, why do you hang around?
The ceo's job is to build shareholder value and the ceo of a developmental stage biotech company does that by developing a drug pipeline. Stockathlete is right, you have to be patient. If you don't think he's doing a good job, vote by selling your shares. On the other hand, if you like the company's new-drug prospects, again, you have to be patient. The ceo can only do so much in moving the stock price up....
3DimensionalResearch research recently recommended PKG, you can see their very comprehensive report on SeekingAlpha. They also recommended IP several years ago, but they closed out that position some time ago, according to the 3DR website.
Sentiment: Strong Buy
Whether it's 2.5 million or 5.5 million or 15.5 million, the exercise of those options have no bearing on the market price since it's the company issuing the shares. If anything, it's not a good thing because the number of shares outstanding is increasing.
It's a non-story as far as I'm concerning. We all want good news but let's not create fiction that some folks will look forward to, in vain.
I have no basis to comment on SNY buying MNKD shares but your point about officers and directors exercising their options and buying stock has one major flaw. When company issued options are exercised, the insiders are buying stock directly from the company, meaning no upward pressure on the stock price or any pressure on shorts.
As you've noted, the company had 4 major milestones achieved since August 2013. So, you concede management has done what they set out to do. As for dilution, would you have preferred if they folded up and closed shop due to lack of funds? They obviously did what they had to do to keep things going. The stock price, meantime, is completely out of their control. Management does what it has to do and hopes investors will reward it with a good stock price. For this we wait. As for only Alfred Mann benefiting from the dilution, what the heck are you talking about? How did he benefit from the dilution? His ownership stake didn't increase all that much even though he put in a lot more money to keep things going. Please grow up or sell your shares and get lost.